From the recent investor update so of course you are correct...

From the recent investor update so of course you are correct Akki. Well spotted, not sure what i was thinking. I think i was confusing it with obj who have been looking at surface cleaning. According to the same update they rate our current status of effective delivery at 75% complete so looking good. One phylomer which fulfilled all criteria and dozens of others still to be tested. I wonder wha t the next news will be as the extension is now 9 months ago.

From the investor update
Current activities: Genentech Collaboration
 Project with Genentech (Roche) – leading biotechnology company in the US
 Our collaboration aims at the isolation of Phylomers that can help killing multi-drug resistant “super bugs”
– Phylomers are expected to increase the potential to kill bacteria which can cause pneumonia,
urinary tract infections, meningitis and sepsis in people with a weakened immune system
 The principle:
13
GNE #1 2014 – 6 month pilot study US $ 150,000
GNE #2 2015 - Resulted in the isolation of one Phylomer, which fulfilled all the criteria
& dozens of additional potential hits, which have not been tested yet
GNE #3 2017 - Screening against additional super bugs US $ 2,000,000
Benefits for Phylogica?
 Revenue; Platform development; Proof of continued interest of big pharma in PYC’s platform